A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.

1 天前 · Among 3222 participants without baseline diabetes, 61.4% had prediabetes, with a median (IQR) HbA 1c of 5.8% (5.5-6.0%). Over a median follow-up of 31.3 months, 8.1% of these participants developed new-onset diabetes, with finerenone vs placebo reducing the risk by 24% (hazard ratio [HR], 0.76; P =.026). Those developing diabetes were younger, had higher BMI and HbA 1c, and were more likely to ...

1 天前 · Empagliflozin use can reduce the risk of calcium and uric acid kidney stones in patients without diabetes, new data show. In the double-blind, single-center, phase 2 SWEETSTONE trial (ClinicalTrials.gov: NCT04911660), investigators randomly assigned 53 adults without diabetes who experienced at least 1 calcium or uric acid kidney stone to receive empagliflozin 25 mg once daily or placebo for 2 ...

4 天之前 · Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the medical community currently understands. In a discovery study, investigators generated an atlas of ...

6 天之前 · Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in patients with and without type 2 diabetes, a new meta-analysis finds.

6 天之前 · The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD).. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial ...

2024年3月27日 · Following acquisition of the CGM, participants had a mean HbA1c decrease of 1.5% (SD, 2.0; P < .001). In subgroup analyses, participants who initiated GLP-1 therapy more than 1 year before acquiring the CGM had mean HbA 1c level reductions of 1.2% (SD, 1.8; P < .001). The researchers also noted HbA 1c improvements regardless of GLP-1 type and bolus insulin use, with mean HbA 1c decreases of:

Type 2 diabetes mellitus is a metabolic disorder characterized by dysregulation of blood glucose caused by relative insulin deficiency and insulin resistance. 1 It is a progressive condition that have serious adverse effects on multiple organs and body functions, but it can be successfully managed with treatment that usually includes lifestyle …

2024年1月12日 · The American Diabetes Association (ADA) has updated its guidelines for the “Standards of Care” for patients with diabetes. The report has been published in Diabetes Care.. In the 2024 update, the ADA focused on patient-centered care, person-first language, and updated screening and treatment approaches based on the latest clinical evidence.

2024年6月14日 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Glucagon-like peptide-1 (GLP-1) is a hormone released when food is eaten to slow gastric emptying, the process by which food leaves the stomach, so that the body can absorb nutrients from food.